ANALYSIS OF WILD-TYPE AND E-ANTIGEN-DEFECTIVE HEPATITIS-B VIRUSES DURING THE COURSE OF A SHORT-TERM CORTICOSTEROID-THERAPY IN CHRONIC HEPATITIS-B

被引:9
作者
DAIKOKU, M
NAKATA, K
HAMASAKI, K
IDO, A
NAKAO, K
KATO, YJ
KOGA, M
YANO, M
NAGATAKI, S
机构
[1] NAGASAKI UNIV,SCH MED,DEPT INTERNAL MED 1,NAGASAKI 852,JAPAN
[2] NAGASAKI CHUO NATL HOSP,INST CLIN RES,NAGASAKI,JAPAN
关键词
HEPATITIS B VIRUS; MUTANT HBV83; HBE SEROCONVERSION;
D O I
10.1002/jmv.1890470213
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Hepatitis B virus (HBV), with a G-to-A point mutation at nucleotide 83 in the precore region (mutant HBV83), accounts for most cases of hepatitis B e antigen (HBeAg)-defective HBV. However, it is still not clear how mutant HBV83 is associated with HBe seroconversion. Twenty-six HBeAg-positive patients with chronic hepatitis B who received oral prednisolone (30 mg/day) for 3 weeks were studied to clarify the prevalence of mutant HBV83 during the treatment using polymerase chain reaction with a restriction fragment length polymorphism assay. Twelve (46%) patients seroconverted to anti-HBe 1 year after treatment, whereas 14(54%) did not. The proportion of mutant HBV83 to whole HBV remained unchanged in both groups during an acute exacerbation induced by withdrawal of corticosteroids. Among 12 anti-HBe-seroconverted patients, five (56%) of nine patients with only wild-type HBV at baseline developed detectable levels of mutant HBV83 while all three patients with a mixed viral population of wild-type HBV and mutant HBV83 at baseline developed a higher proportion of mutant HBV83 one year after treatment. In contrast, these changes were observed in only one (14%) of seven who failed to seroconvert. The results indicate that a flare-up of hepatitis precedes emergence or selection of mutant HBV83, followed by HBe seroconversion in patients with chronic hepatitis B. (C) 1995 Wiley-Liss, Inc.
引用
收藏
页码:184 / 188
页数:5
相关论文
共 22 条
[1]   CHRONIC HEPATITIS IN HBSAG-CARRIERS WITH SERUM HBV-DNA AND ANTI-HBE [J].
BONINO, F ;
ROSINA, F ;
RIZZETTO, M ;
RIZZI, R ;
CHIABERGE, E ;
TARDANICO, R ;
CALLEA, F ;
VERME, G .
GASTROENTEROLOGY, 1986, 90 (05) :1268-1273
[2]   WILD-TYPE AND E-ANTIGEN-MINUS HEPATITIS-B VIRUSES AND COURSE OF CHRONIC HEPATITIS [J].
BRUNETTO, MR ;
GIARIN, MM ;
OLIVERI, F ;
CHIABERGE, E ;
BALDI, M ;
ALFARANO, A ;
SERRA, A ;
SARACCO, G ;
VERME, G ;
WILL, H ;
BONINO, F .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (10) :4186-4190
[3]  
BRUNETTO MR, 1989, ITAL J GASTROENTEROL, V21, P151
[4]  
CARMAN WF, 1989, LANCET, V2, P588
[5]   CHRONIC PERSISTENT HEPATITIS TYPE-B CAN BE A PROGRESSIVE DISEASE WHEN ASSOCIATED WITH SUSTAINED VIRUS-REPLICATION [J].
FATTOVICH, G ;
BROLLO, L ;
ALBERTI, A ;
GIUSTINA, G ;
PONTISSO, P ;
REALDI, G ;
RUOL, A .
JOURNAL OF HEPATOLOGY, 1990, 11 (01) :29-33
[6]   CHANGES IN THE PREVALENCE OF HBEAG-NEGATIVE MUTANT HEPATITIS-B VIRUS DURING THE COURSE OF CHRONIC HEPATITIS-B [J].
HAMASAKI, K ;
NAKATA, K ;
NAGAYAMA, Y ;
OHTSURU, A ;
DAIKOKU, M ;
TANIGUCHI, K ;
TSUTSUMI, T ;
SATO, Y ;
KATO, Y ;
NAGATAKI, S .
HEPATOLOGY, 1994, 20 (01) :8-14
[7]   A SHORT COURSE OF PREDNISOLONE IN CHRONIC TYPE-B HEPATITIS - REPORT OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
HOOFNAGLE, JH ;
DAVIS, GL ;
PAPPAS, SC ;
HANSON, RG ;
PETERS, M ;
AVIGAN, MI ;
WAGGONER, JG ;
JONES, EA ;
SEEFF, LB .
ANNALS OF INTERNAL MEDICINE, 1986, 104 (01) :12-17
[8]   SEROCONVERSION FROM HEPATITIS-B-E ANTIGEN TO ANTIBODY IN CHRONIC TYPE-B HEPATITIS [J].
HOOFNAGLE, JH ;
DUSHEIKO, GM ;
SEEFF, LB ;
JONES, EA ;
WAGGONER, JG ;
BALES, ZB .
ANNALS OF INTERNAL MEDICINE, 1981, 94 (06) :744-748
[9]   RAPID AND SENSITIVE METHOD FOR THE DETECTION OF SERUM HEPATITIS-B VIRUS-DNA USING THE POLYMERASE CHAIN-REACTION TECHNIQUE [J].
KANEKO, S ;
FEINSTONE, SM ;
MILLER, RH .
JOURNAL OF CLINICAL MICROBIOLOGY, 1989, 27 (09) :1930-1933
[10]   SHORT-TERM CORTICOSTEROID-THERAPY FOR CHRONIC ACTIVE HEPATITIS-B [J].
LASKUS, T ;
CIANCIARA, J ;
LOCH, T ;
SLUSARCZYK, J .
DIGESTION, 1990, 47 (02) :115-120